Abstract:Craniopharyngiomas are rare malignancies of dysembryogenic origin, involving the sellar and parasellar areas. These low-grade, epithelial tumors account for two main histological patterns (adamantinomatous craniopharyngioma and papillary craniopharyngioma), which differ in epidemiology, pathogenesis, and histomorphological appearance. Adamantinomatous craniopharyngiomas typically show a bimodal age distribution (5-15 years and 45-60 years), while papillary craniopharyngiomas are limited to adult patients, especially in the fifth and sixth decades of life. Recently, craniopharyngioma histological subtypes have been demonstrated to harbor distinct biomolecular signatures. Somatic mutations in CTNNB1 gene encoding β-catenin have been exclusively detected in adamantinomatous craniopharyngiomas, which predominantly manifest as cystic lesions, while papillary craniopharyngiomas are driven by BRAF V600E mutations in up to 95% of cases and are typically solid masses. Despite the benign histological nature (grade I according to the World Health Organization classification), craniopharyngiomas may heavily affect long-term survival and quality of life, due to their growth pattern in a critical region for the presence of eloquent neurovascular structures and possible neurological sequelae following their treatment. Clinical manifestations are mostly related to the involvement of hypothalamic-pituitary axis, optic pathways, ventricular system, and major blood vessels of the circle of Willis. Symptoms and signs referable to intracranial hypertension, visual disturbance, and endocrine deficiencies should promptly raise the clinical suspicion for sellar and suprasellar pathologies, advocating further neuroimaging investigations, especially brain MRI. The optimal therapeutic management of craniopharyngiomas is still a matter of debate. Over the last decades, the surgical strategy for craniopharyngiomas, especially in younger patients, has shifted from the aggressive attempt of radical resection to a more conservative and individualized approach via a planned subtotal resection followed by adjuvant radiotherapy, aimed at preserving functional outcomes and minimizing surgery-related morbidity. Whenever gross total removal is not safely feasible, adjuvant radiotherapy (RT) and stereotactic radiosurgery (SRS) have gained an increasingly important role to manage tumor residual or recurrence. The role of intracavitary therapies, including antineoplastic drugs or sealed radioactive sources, is predominantly limited to monocystic craniopharyngiomas as secondary therapeutic option. Novel findings in genetic profiling of craniopharyngiomas have unfold new scenarios in the development of targeted therapies based on brand-new biomolecular markers, advancing the hypothesis of introducing neoadjuvant chemotherapy regimens in order to reduce tumor burden prior to resection. Indeed, the rarity of these neoplasms requires a multispecialty approach involving an expert team of endocrinologists, neurosurgeons, neuro-ophthalmologists, neuroradiologists, radiotherapists, and neuro-oncologists, in order to pursue a significant impact on postoperative outcomes and long-term prognosis.

Semantic query optimization in recursive databases

Craniopharyngioma-An update on metabolic and cognitive complications and new therapy

Distinction of papillary and adamantinomatous craniopharyngioma: Clinical features, surgical nuances and hypothalamic outcomes

The Diagnosis and Treatment of Craniopharyngioma

Hi‐Fi SELEX: A high‐fidelity digital‐PCR based therapeutic aptamer discovery platform

Approach to the patient: New era emerges for craniopharyngioma management

Craniopharyngioma in Pediatrics and Adults

[Disease-free survival after surgical and combined treatment of newly diagnosed craniopharyngiomas in adults]

Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis

Papillary tumor of the pineal region: Histopathological characterization and review of the literature

A Systematic Review of Current Targeted Therapies and Future Perspectives

Papillary Tumours of Pineal Region: A single centre experience in management of 11 cases

The anniversary of RNDr Bozena Kotrlá-Erhardová, D.Sc.

Isolation of viruses by electro-extraction of infected plants. 1977.

RARE-27. Treatment and outcomes in atypical choroid plexus papilloma: a single institution experience

Advances in the treatment of Adamantinomatous craniopharyngioma: How to balance tumor control and quality of life in the current environment: a narrative review

Cribriform-morular Variant of Papillary Thyroid Carcinoma: Report of Three Cases and Review of the Literature.

Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review

Sebaceous and Meibomian Carcinomas of the Eyelid: Recognition, Diagnosis, and Management

Choroid plexus papilloma of the cerebellopontine angle

[Proposal for biologic drugs therapy in rheumatoid arthritis].